Futura Medical has announced stellar data from the first clinical trial of MED2002 (Eroxon™). The data shows not only strong efficacy vs. placebo (p=0.0001), but also an excellent safety & tolerability profile and a faster onset of action than currently approved ED products. We believe the market potential is significant, and will update our forecasts as soon as the commercialisation strategy for the product has been clarified. In our view, the product addresses a significant unmet need: it has been reported that sildenafil (Viagra® and generics) is contraindicated in c. 7.5% of patients otherwise eligible for therapy. In addition, a proportion of patients will likely prefer Eroxon™ over sildenafil as a result of its fast onset of action and topical administration. We re-iterate our highly positive stance on Futura Medical.
